TNX-1900

Phase 2Small molecule

TTonix Pharmaceuticals, Inc.

TNX-1900 is one of 2 small molecule programs targeting Binge Eating Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Binge Eating DisorderRecruiting

Binge Eating DisorderPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Binge Eating Disorder

#DrugCompanyPhaseTrials

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

2 2

TNX-1900

TTonix Pharmaceuticals, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Binge Eating Disorder

NCT05664516

Clinical

Trials by Indication[1]

Migraine1 trial

A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

Completed·TTonix Pharmaceuticals, Inc.·Phase 2·NCT05679908·88 enrolled

Binge Eating Disorder1 trial

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Intranasal Oxytocin in Adults With Binge-eating Disorder

Recruiting·MMassachusetts General Hospital·Phase 2·NCT05664516·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TNX-1900. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TNX-1900 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TNX-1900. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tonix Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTonix Pharmaceuticals, Inc.

TNX-1900

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Migraine1 trial

Binge Eating Disorder1 trial

References

Drug Info

Quick Facts

Related News